(Reuters) - Indivior said on Wednesday its 2018 revenue and adjusted net income would come in below its forecast, hurt by the launch of generic versions of its bestselling opioid addiction treatment in the United States.
India's Dr.Reddy's Laboratories and U.S.-based Mylan NV received approval from the Food and Drug Administration (FDA) last month to launch a generic version of Suboxone Film, which generates 80 percent of Indivior's revenue.
The company previously forecast 2018 net revenue in the range of $1.13 billion to $1.17 billion and adjusted net income of $280 million to $320 million.
(Reporting by Justin George Varghese in Bengaluru; Editing by Amrutha Gayathri)
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app